Chronic kidney disease - Effects on the cardiovascular system

被引:1173
作者
Schiffrin, Ernesto L.
Lipman, Mark L.
Mann, Johannes F. E.
机构
[1] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada
[2] Univ Munich, Schwabing Gen Hosp, Dept Hypertens & Nephrol, Munich, Germany
关键词
atherosclerosis; hypertension; kidney; vasculature;
D O I
10.1161/CIRCULATIONAHA.106.678342
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Accelerated cardiovascular disease is a frequent complication of renal disease. Chronic kidney disease promotes hypertension and dyslipidemia, which in turn can contribute to the progression of renal failure. Furthermore, diabetic nephropathy is the leading cause of renal failure in developed countries. Together, hypertension, dyslipidemia, and diabetes are major risk factors for the development of endothelial dysfunction and progression of atherosclerosis. Inflammatory mediators are often elevated and the renin-angiotensin system is frequently activated in chronic kidney disease, which likely contributes through enhanced production of reactive oxygen species to the accelerated atherosclerosis observed in chronic kidney disease. Promoters of calcification are increased and inhibitors of calcification are reduced, which favors metastatic vascular calcification, an important participant in vascular injury associated with end-stage renal disease. Accelerated atherosclerosis will then lead to increased prevalence of coronary artery disease, heart failure, stroke, and peripheral arterial disease. Consequently, subjects with chronic renal failure are exposed to increased morbidity and mortality as a result of cardiovascular events. Prevention and treatment of cardiovascular disease are major considerations in the management of individuals with chronic kidney disease.
引用
收藏
页码:85 / 97
页数:13
相关论文
共 122 条
[1]  
Amann K, 1998, J AM SOC NEPHROL, V9, P1018
[2]  
Amann K, 2001, J AM SOC NEPHROL, V12, P2040, DOI 10.1681/ASN.V12102040
[3]   Cross-talk between the kidney and the cardiovascular system [J].
Amann, Kerstin ;
Wanner, Christoph ;
Ritz, Eberhard .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (08) :2112-2119
[4]   Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria [J].
Anavekar, NS ;
Gans, DJ ;
Berl, T ;
Rohde, RD ;
Cooper, W ;
Bhaumik, A ;
Hunsicker, LG ;
Rouleau, JL ;
Lewis, JB ;
Rosendorff, C ;
Porush, JG ;
Drury, PL ;
Esmatjes, E ;
Raz, I ;
Vanhille, P ;
Locatelli, F ;
Goldhaber, S ;
Lewis, EJ ;
Pfeffer, MA .
KIDNEY INTERNATIONAL, 2004, 66 :S50-S55
[5]  
Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365
[6]   Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease [J].
Blacher, J ;
Guerin, AP ;
Pannier, B ;
Marchais, SJ ;
London, GM .
HYPERTENSION, 2001, 38 (04) :938-942
[7]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[8]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[9]  
Budisavljevic MN, 1996, J AM SOC NEPHROL, V7, P978
[10]   Bone morphogenetic proteins [J].
Chen, D ;
Zhao, M ;
Mundy, GR .
GROWTH FACTORS, 2004, 22 (04) :233-241